IRadimed Corporation (IRMD) has a consensus analyst rating of Buy, based on 2 analysts covering the stock. Of those, 2 recommend buying, 0 recommend holding, and 0 recommend selling.
The analyst consensus price target for IRMD is $120.00, representing a +28.3% upside from the current price of $93.56. Price targets range from a low of $120.00 to a high of $120.00.
